We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: FDA approval
MedXY News
EnglishTag

FDA approval

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major Depression
newsclinical trial evaluationgepirone ER

Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major Depression

By MedXY|Aug 11, 2026

This article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tran

Addressing Critical Barriers to Corneal Cross-Linking in US Keratoconus Care: Navigating the Transition from Photrexa® to Epioxa™
news
corneal cross-linking
FDA approval

Addressing Critical Barriers to Corneal Cross-Linking in US Keratoconus Care: Navigating the Transition from Photrexa® to Epioxa™

By MedXY|Aug 2, 2026

This article examines disparities in access to corneal cross-linking (CXL) for keratoconus patients in the US, highlighting challenges posed by high costs, insurance limitations, and the transition from Photrexa® to Epioxa™.

FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for Children
GastroenterologyconstipationFDA approval

FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for Children

By MedXY|Nov 6, 2025

The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.

Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment
newsatropineFDA approval

Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment

By MedXY|Nov 4, 2025

The FDA has rejected Sydnexis’s low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy
NephrologyFDA approvallupus nephritis

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY|Dec 18, 2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis managem

Evaluating the Clinical Generalizability of FDA-Approved AI-Enabled Medical Devices: Insights and Implications
AIFDA approval

Evaluating the Clinical Generalizability of FDA-Approved AI-Enabled Medical Devices: Insights and Implications

By MedXY|Oct 6, 2025

A comprehensive analysis of 903 FDA-approved AI medical devices reveals limited clinical performance data and demographic inclusivity, underscoring the need for ongoing evaluation to ensure safe, effective clinical application.

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer
Clinical UpdatesFDA approvalHormone Receptor-Positive

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY|Oct 6, 2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemoth

FDA Approves Subcutaneous Lecanemab for Maintenance Treatment in Early Alzheimer’s Disease: A Step Toward More Accessible Care
NeurologyAlzheimer's diseaseFDA approval

FDA Approves Subcutaneous Lecanemab for Maintenance Treatment in Early Alzheimer’s Disease: A Step Toward More Accessible Care

By MedXY|Oct 6, 2025

The FDA has approved a subcutaneous form of lecanemab for maintenance therapy in early Alzheimer’s, offering similar clinical benefits to IV dosing with improved convenience and safety, potentially transforming patient care delivery.

FDA Approves Updated COVID-19 Vaccines Targeting Latest LP.8.1 Variant for High-Risk and Older Adults
Public HealthCOVID-19FDA approval

FDA Approves Updated COVID-19 Vaccines Targeting Latest LP.8.1 Variant for High-Risk and Older Adults

By MedXY|Oct 5, 2025

The FDA has authorized updated COVID-19 vaccines from Pfizer and Moderna designed to target the LP.8.1 sublineage, expanding vaccination to adults over 65 and individuals with high-risk conditions, enhancing immune defense against evolving

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management
Clinical Updatesartificial intelligenceclinical decision support

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management

By MedXY|Aug 19, 2025

ArteraAI Prostate, the first FDA-approved AI-driven multimodal software, offers personalized clinical decision support for localized prostate cancer, improving treatment precision and reducing overtreatment risks.

FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia
NeurologyFDA approvalfibromyalgia

FDA Approves Tonmya: First Nonopioid Sublingual Treatment Targeting Sleep in Fibromyalgia

By MedXY|Oct 4, 2025

The FDA has approved Tonmya (sublingual cyclobenzaprine) as the first new fibromyalgia therapy in 15 years, targeting nonrestorative sleep to alleviate pain, fatigue, and cognitive symptoms in adults.

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief
Clinical Updatesdry eye diseaseFDA approval

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

By MedXY|Oct 1, 2025

Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review
Clinical UpdatesFDA approvalphase 3 trials

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

By MedXY|Oct 1, 2025

The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review
Clinical UpdatesFDA approvalgrowth hormone deficiency

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

By MedXY|Sep 30, 2025

Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.

FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention
HIV/AIDSFDA approvalHIV prevention

FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention

By MedXY|Sep 30, 2025

Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.

FDA Approves Sephience: A New Oral Therapy for Phenylketonuria
Internal MedicineFDA approval

FDA Approves Sephience: A New Oral Therapy for Phenylketonuria

By MedXY|Sep 30, 2025

The FDA has approved Sephience, an oral therapy for phenylketonuria (PKU), offering a novel treatment option for both children and adults with this rare metabolic disorder.

FDA Expands Skytrofa Approval to Adults with Growth Hormone Deficiency: Clinical and Practice Implications
Clinical UpdatesFDA approvalgrowth hormone deficiency

FDA Expands Skytrofa Approval to Adults with Growth Hormone Deficiency: Clinical and Practice Implications

By MedXY|Sep 30, 2025

Once-weekly lonapegsomatropin (Skytrofa) is now FDA-approved for adult growth hormone deficiency, offering a more convenient alternative to daily injections with demonstrated efficacy and safety.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities